Bruno Fagali and the Future of Brazilian Law

     Mr. Bruno Jorge Fagali is a notable lawyer from Brazil who has been in practice since 2008.Although he has been in the field for only a few years, he has established a reputation for himself as an expert in several of the areas of law.

Mr. Bruno Jorge Fagali received his higher education at the Pontifical Catholic University – a Brazilian institution in the city of Sao Paulo. In 2008, Mr. Bruno Jorge Fagali graduated and entered the world of legal practice. In 2016 and graduated with his master’s as well. Mr. Bruno Jorge Fagali’s majors are the law of the state, administrative law, and anti-corruption law. Later he continued to expand upon his expertise and studied the fields of compliance and ethics, among else.

Mr. Bruno Jorge Fagali started gaining experience early on in his studies. He took internships and volunteered many times in order to gain as much practice as possible during his years of study. Practical experience is extremely valuable in the field of law.

After he had graduated, Mr. Bruno Jorge Fagali was on the board of a few institutions such as the Society of Corporate Compliance and Ethics and the Brazilian Institute of Law and Corporate Ethics. He has also worked at a few law firms such as the Radi, Call and Associados advocacy at the law firm of Nova/ sb. Mr. Bruno Jorge Fagali has experience at positions such as board member, lawyer, and more. He works in the fields of public law, compliance, and the likes.


Labaton Sucharow’s SEC Whistleblower Lawyer Files Lawsuit Against Biogen Incorporation

Biogen Inc is being sued by Electrical Workers Pension Fund for falsifying its financial reports and disclosures on immunosuppressant, Tecfidera. Labaton Sucharow’s SEC Whistleblower attorney filed a securities lawsuit against the biopharmaceutical company on October 20th, 2016. Court documents stated Biogen violated the Securities Exchange Act of 1934 and the U.S. Securities and Exchange Commission Rule. Labaton Sucharow Law Firm is representing the Pension Fund, investors and absent members who were misinformed about the growth and sales of Tecfidera. Investors were affected if they bought publicly traded securities from July 23rd, 2014 through July 23rd, 2015.


Biogen and specific executives were named in the Electrical Workers Pension Fund v. Kingsley class action lawsuit and accused of hyping the safety of Tecfidera and disclosing dishonest growth potentials. Tecfidera is used by medical physicians to treat multiple sclerosis and was the company’s leading product to generate revenue. The law suit alleges Biogen was aware the product was causing the immune system to weaken. Physicians stopped using the immunosuppressant to treat their patients, which resulted in a reduction of Biogen’s revenue.


In July 2015, the company quickly reduced its revenue by 50 percent based on revisions to their expectations of the growth of Tecfidera. Biogen’s common stock took more than a 22 percent plunge, causing stock prices to drop by $85.02 per share.


SEC Whistleblower lawyer representing Labaton Sucharow Law Firm encourages investors and entities to seek appointment as lead plaintiff if they are shareholders in Biogen publicly traded securities between July 2014 and July 2015. There is no requirement to seek appointment as lead plaintiff to receive financial recovery in the class action if the judge rules in favor of Electrical Workers Pension Fund. The court appoints lead plaintiff as a representative for absent members.


To inquire about the Electrical Workers Pension Fund v. Kingsley action, contact Labaton Sucharow and speak with Francis P. McConville. She is available to answer all questions regarding the case and how to serve as lead plaintiff. Labaton is the leading SEC Whistleblower law firm in the nation to represent investors, funds, and whistleblowers. Visit Labaton’s SEC Whistleblower Advocacy online to search for informative resources relating to the whistleblower program and the Dodd-Frank Act.